arrow
K

Kellie N. Smith

Johns Hopkins University
H指数:30
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells

轻度HIV特异性选择压力叠加于自然CD4+ T细胞动力学,解释了HIV储库细胞的克隆性和衰减动力学。

2025-09-220
PREAI
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer

一项关于HPV16 L2E7E6融合蛋白疫苗接种后治疗HPV16+宫颈癌的随机试点研究

2025-08-200
PRE
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

帕博利珠单抗联合放疗在免疫冷型非小细胞肺癌中诱导系统性抗肿瘤免疫应答

2025-07-220
OA
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

新辅助nivolumab或nivolumab联合LAG-3抑制剂relatlimab治疗可切除食管/胃食管交界处癌: Ib期试验和ctDNA分析

2024-03-1913
OAAI
Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response
2023-09-2916
OA
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

Durvalumab联合卡介苗 (BCG) 或体外放射治疗对BCG无反应的非肌肉浸润性膀胱癌患者的1期试验: Hoosier癌症研究网络GU16-243 ADAPT-bt研究

2023-06-0119
OA
Persistent mutation burden drives sustained anti-tumor immune responses in human cancers
2023-04-041
PRE
Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer
2023-04-040
PRE